The book reviews clinical trial methodology as it pertains to drug
development in psychiatry. The reader will understand the process
of drug development in psychiatry from discovery through marketing
with the help of clinically relevant examples. The reader will
appreciate the history of drug development in psychiatry dating
back to the era of serendipitous discovery and culminating in an
era of new and highly focused targets. Readers will understand how
drug development in psychiatry has changed and adapted with the
discovery of novel mechanism of action drugs. Novel drugs and
disease targets have changed the way developers and regulatory
agencies think about clinical trial methodology. The book
elucidates how biomarkers, genetics and advances in neuroscience
and neuroimaging have influenced drug development approaches, which
will ultimately change the practice of psychiatry. The book will be
broken down into the following sections:
a.       Prior to the
1960s - Drug discovery by chance observation
b.      The last 50 years –
refined targeting of CNS drugs without the discovery of
mechanistically new drugs
c.      The future – the
discovery and development of mechanistically new drugs. The
examination of new targets, genetics and biomarkers.Â
General
Imprint: |
Springer International Publishing AG
|
Country of origin: |
Switzerland |
Series: |
Advances in Neurobiology, 30 |
Release date: |
March 2023 |
First published: |
2023 |
Editors: |
Matthew Macaluso
• Sheldon H. Preskorn
• Richard C. Shelton
|
Dimensions: |
235 x 155mm (L x W) |
Format: |
Hardcover
|
Pages: |
459 |
Edition: |
1st ed. 2023 |
ISBN-13: |
978-3-03-121053-2 |
Categories: |
Books
|
LSN: |
3-03-121053-0 |
Barcode: |
9783031210532 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!